An intervention study of the general practice management of older adults with cardiovascular metabolic comorbidities
Abstract
Purpose: To investigate the impact of general practice management on treatment compliance, lifestyle, and clinical indicators in older adults with cardiovascular metabolic comorbidities to provide more effective disease management strategies for this population.
Patients and methods: This randomized controlled trial enrolled 200 older adults with type 2 diabetes and established atherosclerotic cardiovascular disease (e.g., coronary heart disease, ischemic stroke) who were discharged from Qinhuangdao First Hospital between November 2021 and May 2023. Patients were randomly divided into intervention and control groups (n = 100 per group). The intervention group received general medical management, including personalized health education during hospitalization, community outpatient follow-up after discharge, and lifestyle interventions. The control group received routine discharge guidance. Changes in medication usage, body mass index (BMI), smoking rate, and clinical indicators, such as glycated hemoglobin, low-density lipoprotein cholesterol, and creatinine levels were evaluated over a 12-month follow-up period. Dietary intake and physical activity were assessed using the Semi-Quantitative Food Frequency Survey Questionnaire and the Physical Activity Scale for the Elderly, respectively.
Results: After 12 months, 91 controls and 95 intervention patients remained and were analyzed per-protocol. Within-group analyses revealed that the intervention group successfully maintained…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.